ATE:CC News and Press, Antibe Therapeutics Inc. From 08/21/23

Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite Canada NewsWire TORONTO , Aug. 21, 2023 /CNW/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview ...

- Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study - PK/PD study results expected next quarter with Phase II initiation in calendar Q1 2024 - Ended quarter with $34.3 million in cash and equivalents Antibe Therapeutics Inc. (TSX: ATE, OTCQX: AT...

- Completed transition to otenaproxesul’s new formulation; tablet manufacturing underway - PK/PD study results expected in calendar Q4 2023 with Phase II initiation in Q1 2024 - Ended year with $38.9 million in cash and equivalents Antibe Therapeutics Inc. (TSX: ATE, OTCQX: A...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the Precision in Clinical Trials Summit being held in Boston on May 1 ȁ...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference being held in...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK/PD Study for Otenaproxesul’s New Formu...

- Recent animal data on otenaproxesul's new formulation confirm rapid drug uptake and potential for effective pain management - Targeting first clinical dose in calendar Q3 2023; Phase II top-line data within 12 months - Ended quarter with $42.4 million in cash and equivalents, provid...

- Progress includes otenaproxesul’s new formulation, strengthened IP and robust third-party sales projections - Sale of Citagenix subsidiary provides non-dilutive funding - Ended quarter with $45.4 million in cash and equivalents, providing over two ye...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to announce the closing of the sale of its Citagenix Inc. subsidiary to HANSAmed Limited (&#...

- Patent application filed for improved formulation; strengthens IP protection to 2042 - Anticipated benefits include faster onset of action, lower doses - Phase II molar study no longer required; Phase II bunionectomy study on track for H1 2023 A...